Emergence client, Delivra, announces partnership in the medical cannabis research, development and commercialization markets

March 23, 2017

Burlington, Ontario-and Charlottetown, PEI-based Emergence client, Delivra, has announced  a strategic partnership with Dosecann Inc. and ARA-Avanti Rx Analytics Inc. to develop a unique suite of standardized products for the medical cannabis research, development, and commercialization markets.


Dr. Joe Gabriel, CEO, Delivra

“The Federal Government of Canada has numerous concerns, and barriers to overcome, before legalizing cannabis, including stricter regulatory controls. The partnership between the three companies addresses many of these concerns, providing greater safety and efficacy of medical cannabis specific products for the patient, with products that provide consistent, accurate dosing, and that are manufactured under pharmaceutical GMP Standards,” Dr. Joseph Gabriele, Delivra’s Chief Executive Officer, told us.

The collaboration between Delivra, Dosecann and Avanti addresses an exploding field of medicine by seeking to standardize, validate, package and distribute cannabis products in innovative mono-dose delivery platforms to licensed producers and other future legal distribution networks.

delivra1According to Gabriele: “This agreement both validates Delivra’s proprietary transdermal platform technology and allows Delivra to capitalize on an unmet need in the pain market: to provide quality, accuracy, consistency and repeatable dosing using cannabis-based therapeutics.”

“This three-way joint venture with Delivra and Avanti enables us to potentially formulate, manufacture and distribute medical cannabis products that are standardized, quality controlled and provided through unique delivery platforms effectively dosing medical cannabis,” said Greg Boone, Founder of Dosecann.

For further information about this partnership, click here!

See also:  Emergence client, Delivra Corp’s LivRelief products to be distributed across Canada in single dose size and Emergence client, Delivra, set for US product launch


Delivra Corp. is a specialty biotechnology company that has a proprietary transdermal delivery system platform that can shuttle pharmaceutical and natural molecules, through the skin, in a targeted specific manner. Delivra manufactures and sells a growing line of natural topical creams with the proprietary transdermal delivery system platform under the LivReliefTM brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and under the LivSportTM brand for sports performance. Further information on Delivra can be found at www.delivracorp.com, www.livrelief.com.


ARA-Avanti Rx Analytics Inc. is the first Health Canada GMP and OCDS approved Contract Organization specializing in the field of controlled drugs and substances particularly in the area of Medicinal Marijuana, HEMP, Cannabinoids, and Marijuana based concentrated products.


Dosecann is a private specialty pharma company that has built a team of seasoned scientists, doctors and business leaders. We offer unique solutions to the emerging cannabis industry for numerous medical conditions.